2-cyano-N-{3-[2-cyano-3-(3,4,5-trihydroxyphenyl)-acryloylamino]propyl}-3-(3,4,5-trihydroxyphenyl)-acrylamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-cyano-N-{3-[2-cyano-3-(3,4,5-trihydroxyphenyl)-acryloylamino]propyl}-3-(3,4,5-trihydroxyphenyl)-acrylamide
• 英文别名: 2-cyano-N-{3-[2-cyano-3-(3,4,5-trihydroxyphenyl)-acryloylamino]-propyl}-3-(3,4,5-trihydroxyphenyl)-acrylamide；(E)-2-cyano-N-[3-[[(E)-2-cyano-3-(3,4,5-trihydroxyphenyl)prop-2-enoyl]amino]propyl]-3-(3,4,5-trihydroxyphenyl)prop-2-enamide
• 化学式: C₂₃H₂₀N₄O₈
• 分子量: 480.434
• InChiKey: AAPVOSBVTLGGOU-VHUAAIQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  227
• 氢给体数：
  8
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3,4,5-三羟基苯甲醛 、 2-cyano-N-[3-(2-cyanoacetylamino)propyl]acetamide 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以70%的产率得到2-cyano-N-{3-[2-cyano-3-(3,4,5-trihydroxyphenyl)-acryloylamino]propyl}-3-(3,4,5-trihydroxyphenyl)-acrylamide
  参考文献：
  名称：

  Parallel Solution-Phase Synthesis of Targeted Tyrphostin Libraries with Anticancer Activity

  摘要：

  半自动化、优雅的合成和并行溶液相合成方法的结合，使我们开发出了五个有针对性的对称酪磷脂化合物库。这些化合物库平均由 12 个化合物组成。尽管如此，我们还是发现了针对 HT29（结直肠癌）和 G401（肾癌）细胞系的低微摩尔强效生长抑制剂。此外，我们还获得了重要的 SAR 数据。我们注意到，具有 2-氯苯基的类似物始终具有最强的生长抑制活性（10：GI50 HT29 5.5 ± 0.4 μM，GI50 G401 2.6 ± 0.4 μM；23：GI50 HT29 2.4 ± 0.2 μM，GI50 G401 1.9 ± 1 μM；34：GI50 HT29 8.8 ± 0.2 μM，GI50 G401 1.9 ± 1 μM）：对于 34：GI50 HT29 8.8 ± 3.1 μM，GI50 G401 6.2 ± 2.9 μM；对于 46：GI50 HT29 5.2 ± 0.9 μM，GI50 G401 3.7 ± 0.6 μM；对 57：GI50 HT29 4.6 ± 0.8 μM，GI50 G401 2.1 ± 0.2 μM）、3-氯苯（对 11：GI50 HT29 3.8 ± 0.7 μM，GI50 G401 1.7 ± 0.7 μM；对于 48：GI50 HT29 5.9 ± 0.1 μM，GI50 G401 3.4 ± 0.6 μM；对于 58：GI50 HT29 4.8 ± 0.9 μM，GI50 G401 3.4 ± 0.2 μM），或 3-甲氧基苯基取代基（对于 13：GI50 HT29 7.4 ± 3.8 μM，GI50 G401 2.8 ± 0.5 μM；对于 26：对于 26：GI50 HT29 4.5 ± 0.5 μM，GI50 G401 4.9 ± 1 μM；对于 37：GI50 HT29 3.7 ± 0.2 μM，GI50 G401 1.6 ± 0.2 μM；49：GI50 HT29 3.7 ± 0.4 μM，GI50 G401 3.4 ± 0.2 μM；60：GI50 HT29 4.1 ± 0.6 μM，GI50 G401 1.8 ± 0.3 μM）。最后，我们注意到，增加末端芳香环之间的距离对 2-、3-氯苯基和 3-甲氧基苯基类似物的影响很小，但对 OH、COOH 和多重取代的类似物有有利影响。

  DOI：

  10.1071/ch04143

文献信息

• [EN] METHODS AND AGENTS FOR INHIBITING DYNAMIN-DEPENDENT ENDOCYTOSIS<br/>[FR] PROCEDES ET AGENTS POUR INHIBER L'ENDOCYTOSE DEPENDANT DE LA DYNAMINE
  申请人：UNIV NEWCASTLE RES ASS

  公开号：WO2005049009A1

  公开（公告）日：2005-06-02

  There are disclosed methods for inhibiting dynamin-dependent endocytosis in cells comprising treating the cells with an effective amount of a compound of formula (I), or a dimeric tyrphostin, physiologically acceptable salt, or prodrug thereof. Compounds useful in the methods described are also provided. The inhibition of dynamin-dependent endocytosis of cells is applicable to the treatment of epilepsy and neurological disorders and conditions.

  抑制细胞中依赖动力蛋白的内吞作用的方法已被披露，包括将细胞用式(I)的化合物、二聚酪酪激酶抑制剂、生理上可接受的盐或其前药的有效量进行处理。还提供了所述方法中有用的化合物。抑制细胞中依赖动力蛋白的内吞作用适用于治疗癫痫和神经系统疾病和症状。
• Parallel Solution-Phase Synthesis of Targeted Tyrphostin Libraries with Anticancer Activity
  作者：Timothy A. Hill、Jennette A. Sakoff、Phillip J. Robinson、Adam McCluskey

  DOI：10.1071/ch04143

  日期：——

  The combination of semi-automation, an elegant synthesis, and parallel solution-phase synthesis approaches has allowed the development of five targeted, symmetrical tyrphostin compound libraries. These libraries on average are comprised of 12 compounds. Notwithstanding this, low micromolar potent growth inhibitors against HT29 (colorectal carcinoma) and G401 (renal carcinoma) cell lines were discovered. Additionally, significant SAR data was obtained. We noted that the most potent growth inhibitory activity was consistently observed for those analogues that possessed a 2-chlorophenyl (for 10: GI50 HT29 5.5 ± 0.4 μM, GI50 G401 2.6 ± 0.4 μM; for 23: GI50 HT29 2.4 ± 0.2 μM, GI50 G401 1.9 ± 1 μM; for 34: GI50 HT29 8.8 ± 3.1 μM, GI50 G401 6.2 ± 2.9 μM; for 46: GI50 HT29 5.2 ± 0.9 μM, GI50 G401 3.7 ± 0.6 μM; for 57: GI50 HT29 4.6 ± 0.8 μM, GI50 G401 2.1 ± 0.2 μM), a 3-chlorophenyl (for 11: GI50 HT29 3.8 ± 0.7 μM, GI50 G401 1.7 ± 0.7 μM; for 48: GI50 HT29 5.9 ± 0.1 μM, GI50 G401 3.4 ± 0.6 μM; for 58: GI50 HT29 4.8 ± 0.9 μM, GI50 G401 3.4 ± 0.2 μM), or a 3-methoxyphenyl substituent (for 13: GI50 HT29 7.4 ± 3.8 μM, GI50 G401 2.8 ± 0.5 μM; for 26: GI50 HT29 4.5 ± 0.5 μM, GI50 G401 4.9 ± 1 μM; for 37: GI50 HT29 3.7 ± 0.2 μM, GI50 G401 1.6 ± 0.2 μM; for 49: GI50 HT29 3.7 ± 0.4 μM, GI50 G401 3.4 ± 0.2 μM; for 60: GI50 HT29 4.1 ± 0.6 μM, GI50 G401 1.8 ± 0.3 μM). Finally, we noted that increasing the distance between the terminal aromatic rings had only a minimal effect on the 2-, 3-chlorophenyl, and 3-methoxyphenyl analogues, but did have a favourable effect on OH, COOH, and multiply substituted analogues.

  半自动化、优雅的合成和并行溶液相合成方法的结合，使我们开发出了五个有针对性的对称酪磷脂化合物库。这些化合物库平均由 12 个化合物组成。尽管如此，我们还是发现了针对 HT29（结直肠癌）和 G401（肾癌）细胞系的低微摩尔强效生长抑制剂。此外，我们还获得了重要的 SAR 数据。我们注意到，具有 2-氯苯基的类似物始终具有最强的生长抑制活性（10：GI50 HT29 5.5 ± 0.4 μM，GI50 G401 2.6 ± 0.4 μM；23：GI50 HT29 2.4 ± 0.2 μM，GI50 G401 1.9 ± 1 μM；34：GI50 HT29 8.8 ± 0.2 μM，GI50 G401 1.9 ± 1 μM）：对于 34：GI50 HT29 8.8 ± 3.1 μM，GI50 G401 6.2 ± 2.9 μM；对于 46：GI50 HT29 5.2 ± 0.9 μM，GI50 G401 3.7 ± 0.6 μM；对 57：GI50 HT29 4.6 ± 0.8 μM，GI50 G401 2.1 ± 0.2 μM）、3-氯苯（对 11：GI50 HT29 3.8 ± 0.7 μM，GI50 G401 1.7 ± 0.7 μM；对于 48：GI50 HT29 5.9 ± 0.1 μM，GI50 G401 3.4 ± 0.6 μM；对于 58：GI50 HT29 4.8 ± 0.9 μM，GI50 G401 3.4 ± 0.2 μM），或 3-甲氧基苯基取代基（对于 13：GI50 HT29 7.4 ± 3.8 μM，GI50 G401 2.8 ± 0.5 μM；对于 26：对于 26：GI50 HT29 4.5 ± 0.5 μM，GI50 G401 4.9 ± 1 μM；对于 37：GI50 HT29 3.7 ± 0.2 μM，GI50 G401 1.6 ± 0.2 μM；49：GI50 HT29 3.7 ± 0.4 μM，GI50 G401 3.4 ± 0.2 μM；60：GI50 HT29 4.1 ± 0.6 μM，GI50 G401 1.8 ± 0.3 μM）。最后，我们注意到，增加末端芳香环之间的距离对 2-、3-氯苯基和 3-甲氧基苯基类似物的影响很小，但对 OH、COOH 和多重取代的类似物有有利影响。
• Use of endocytosis inhibitors and antibodies for cancer therapy
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：US10253107B2

  公开（公告）日：2019-04-09

  The present invention relates to the use of endocytosis inhibitors, including clathrin-dependent endocytosis inhibitors such as inhibitors of dynamin and antibodies, for enhancing the immune response to cancer, and thereby treating cancers including cancer associated receptor positive cancers.

  本发明涉及内吞抑制剂的使用，包括凝集素依赖性内吞抑制剂，例如达纳明抑制剂和抗体，用于增强对癌症的免疫反应，从而治疗癌症，包括癌症相关受体阳性癌症。
• USE OF DYNAMIN RING STABILIZERS
  申请人：Children's Medical Research Institute

  公开号：EP2432465B1

  公开（公告）日：2015-07-22
• USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY
  申请人：The University Of Queensland

  公开号：EP2911692B1

  公开（公告）日：2019-08-21